Hormone replacement therapy (HRT) and GLP-1 medications are different tools, but they keep showing up in the same conversation. The reason is timing: the life stages when people reach for hormones — menopause in women, low testosterone in men — are also the stages of weight gain and body-composition change that bring people to a GLP-1.
What "HRT" covers
- For women: menopausal hormone therapy — estrogen, usually with a progestogen — for menopausal symptoms and bone protection.
- For men: testosterone replacement therapy (TRT) for diagnosed hypogonadism.
Both replace a hormone the body is short on. Neither is a weight-loss drug, and neither is a GLP-1. That's the single most useful thing to hold onto.
Who benefits (the short version)
- Women — those with moderate-to-severe menopausal symptoms or a need for bone protection; individualized by timing and personal risk. → see HRT for women and GLP-1 medications.
- Men — those with genuine hypogonadism; but obesity-related low testosterone is often reversible without TRT. → see HRT for men and GLP-1 medications.
Why GLP-1s are part of the conversation
- Shared terrain. Menopause and obesity-related low testosterone both involve gaining fat (especially visceral) and losing muscle — the same body-composition problems a GLP-1 addresses through weight loss.